智通财经APP获悉，康希诺生物(06185)跌逾 5%。消息面上，隔夜美股莫得纳大跌逾17%，其与默克联合研发的个性化黑色素瘤疫苗三期临床试验数据意外提前泄露，结果未达市场今年早些时候形成的高预期。今年8月，莫得纳宣布这款定制疫苗如与默克畅销药Keytruda联合使用，可显著降低这种致命肿瘤的复发风险，并具有临床意义。
据悉，康希诺已搭建mRNA开发和制备平台，公司旗下康希诺上海此前与德普世生物签署合作框架协议，共同开发mRNA个性化肿瘤疫苗，由康希诺提供mRNA递送及制剂能力，德普世提供AI新抗原发现和设计平台。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.